Australian access & law

Advertising rules for therapeutic goods in Australia apply strictly to medicinal cannabis. See how the TGA framework treats prescription-only products.

How Australia's 2021 CBD down-scheduling actually works, what changed in the Poisons Standard, and why access remains more complicated than headlines suggest.

Prescribed cannabis in the ACT does not exempt you from drug driving laws. Here is how the territory's roadside oral fluid testing framework works.

Prescribed cannabis does not exempt NSW drivers from roadside oral fluid testing. See how the zero-tolerance regime works and what the Poisons Standard says.

Prescribed cannabis is legal in the NT — but driving with detectable THC remains an offence regardless of prescription. Here's how the law actually works.

Prescribed cannabis is lawful in Queensland, but drug driving laws still apply. Here is how the roadside testing rules work under state legislation.

Prescribed cannabis and driving in South Australia: how the zero-tolerance drug-driving law applies, what the Poisons Standard says, and what patients need to know.

Prescribed cannabis and driving in Tasmania: how the presence and impairment offences work, what roadside tests detect, and where the law still has gaps.

Prescribed cannabis is legal in Victoria — but driving with detectable THC is not. Here's how the road rules actually work for patients.

Prescribed cannabis and WA driving law don't mix the way some patients expect. Here's how the state's drug-driving rules actually work.

How a medicine joins the ARTG in Australia: the evaluation pathways, the evidence dossier, and why registration is a quality hurdle, not a customs one.

Dispensing an unapproved medicine in Australia is legal — but only under specific TGA pathways. Here's how the process actually works at the pharmacy counter.

Australia's Personal Importation Scheme lets travellers bring in small quantities of medicines — but the rules for cannabis and controlled drugs are stricter than most people realise.

Medicinal cannabis access in the NT follows federal TGA rules plus a thin layer of Territory law. Here's how the scheduling and pathways actually work.

Medicinal cannabis access in NSW explained: federal scheduling, prescribing pathways, state controls, dispensing and driving rules, with sources to check.

Queensland sits within Australia's federal medicinal cannabis framework, but state-level rules add an extra layer. Here's how access actually works.

How does medicinal cannabis access actually work in South Australia? A plain-language look at scheduling, prescribing pathways, and what SA patients and clinicians need to know.

Tasmania sits inside the same federal medicinal cannabis framework as every other state — but the state layer adds its own wrinkle. Here's how access actually works.

Medicinal cannabis access in the ACT explained: the federal scheduling framework, territory law, and what patients and prescribers should understand.

Victoria sits within Australia's federal medicinal cannabis framework, but state-level rules add another layer. Here's how access actually works.

Medicinal cannabis access in Western Australia explained: TGA scheduling, WA prescriber approvals, dispensing and driving rules, as at mid-2024.

Australia's TGA classifies medicinal cannabis into five product categories. Here's what those categories actually mean for scheduling, access, and who can prescribe what.

Australia draws a hard legal line between medicinal and recreational cannabis. Here's how the scheduling framework actually works — and why the distinction matters.

Patient access data in Australia explained: what the TGA's approval figures show, how SAS and Authorised Prescriber pathways differ, and where gaps remain.

Restricted representations explained: how consent works, how they differ from prohibited ones, and why sponsors of cannabis products need care.

Prescribers accessing cannabis through the SAS or Authorised Prescriber pathway carry strict record-keeping duties. Here's what the law actually requires.

Adverse event reporting is a legal obligation under TGA law — here's how the system works for cannabis medicines in Australia, and why it matters.

Schedule 4 and Schedule 8 sit at the heart of Australia's cannabis access framework. Here's what each classification actually means under the Poisons Standard.

Category A of Australia's Special Access Scheme explained — who it covers, how it works, and where it sits in the TGA's regulatory framework for unapproved medicines.

How the TGA's Special Access Scheme Category B works for unapproved medicines in Australia — the pathway, the paperwork, and what it actually requires.

SAS Category C lets approved suppliers notify the TGA before supplying unapproved medicines. Here's how the pathway actually works, and where it sits in AU cannabis regulation.

Federal scheduling sets the rules, but states enforce them differently. Here's how Australia's split drug regulation system actually works for cannabis access.

TGA GMP licensing sits at the heart of Australia's medicinal cannabis supply chain. Here's how the framework works, and why it matters for product quality.

The ARTG splits medicines into registered and unregistered categories — and for cannabis in Australia, that distinction shapes nearly every access pathway available.

Australia's Authorised Prescriber Scheme gives certain doctors a standing approval to prescribe unapproved medicines. Here's how the pathway actually works.

Australia's Office of Drug Control sits at the centre of medicinal cannabis licensing. Here's how its mandate, licensing tiers and oversight actually work.

The Poisons Standard (SUSMP) determines how every cannabis medicine is scheduled in Australia. Here's how the classification system actually works.

The prescriber's role in access to medicinal cannabis in Australia: who can prescribe, and how the SAS and Authorised Prescriber pathways differ.

Pharmacists do far more than dispense in the medicinal cannabis supply chain. Here's how AU access law actually positions them — and where the complexity lives.

The Therapeutic Goods Administration shapes every legal cannabis pathway in Australia. See how scheduling, the ARTG, SAS and Authorised Prescriber work.

Unapproved therapeutic goods explained: what the term means under the Therapeutic Goods Act 1989, and how lawful supply works through SAS and AP pathways.

The Special Access Scheme is a key pathway for accessing unapproved medicines in Australia. Here is how it works and where it fits in the regulatory system.

The term investigational medicine appears often in research and regulation. Here is what it precisely means and why the distinction is so important.

Prescribed cannabis is a Schedule 8 controlled drug in Australia. Here's what that means for employees facing workplace drug tests.

The Australian Register of Therapeutic Goods is the official database of therapeutic goods that may lawfully be supplied in Australia.

Good Manufacturing Practice (GMP) is a system of quality assurance standards, enforced in Australia by the Therapeutic Goods Administration (TGA), that governs the conditions under which therapeutic goods — including medicines, biologicals, and certain complementary medicines — are manufactured, tested, and released.

A set of conditions under Australian law that permits individuals to import a limited quantity of therapeutic goods for their own personal use without holding an import licence, subject to specific quantity, scheduling, and documentation requirements administered by the Therapeutic Goods Administration (TGA).

Schedule 4 is the Australian classification for substances that may only be supplied on prescription from an authorised health practitioner.

Schedule 8 is the Australian classification for controlled drugs that are subject to strict legal controls on their prescribing, supply and record-keeping.

The Special Access Scheme is an Australian regulatory pathway allowing access to medicines not included on the Australian Register of Therapeutic Goods under defined conditions.

The Therapeutic Goods Act 1989 (Cth) is the principal Commonwealth statute establishing the regulatory framework for the manufacture, supply, import, export, and advertising of therapeutic goods in Australia.